Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

BACKGROUND: Tumour necrosis factor α blockers in rheumatoid arthritis are known to increase the risk of serious infections defined as life-threatening, requiring hospitalisation or intravenous antibiotics. Recently, new biological agents have become available. Their safety is an important issue. PUR...

Descripción completa

Detalles Bibliográficos
Autores principales: Salliot, C, Dougados, M, Gossec, L
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2009
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2596305/
https://www.ncbi.nlm.nih.gov/pubmed/18203761
http://dx.doi.org/10.1136/ard.2007.083188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2596305/
https://www.ncbi.nlm.nih.gov/pubmed/18203761
http://dx.doi.org/10.1136/ard.2007.083188

Ejemplares similares